Was President Trump’s plan to reduce drug prices DOA?
President Trump’s blueprint to lower drug prices hasn’t made it out of the brainstorm phase.
Most recent articles by Sander A. Flaum
Critics who want to cut drug prices must say which ones
Cutting prescription drug prices has become one of the most popular campaign promises of our time.
Paying Lip Service to STEM Isn’t Enough
I’m not suggesting that colleges become vocational schools. But don’t you think they should also help young people prepare for the life they’re going to be living?
Will Investors Reward Drugmakers That Limit Price Increases?
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?
Why Any Merger is the Last Resort of Lousy Marketers
Really? Is this the new healthcare math — the fewer the insurance companies, the greater the competition and the lower the premiums?
Moving Forward — Without the Promotion
Until now, your superiors have promoted you. Now it’s your responsibility to show why you belong.
Why are We Still Shortchanging Women in the Workplace?
Why would any CEO tolerate a corporate culture that holds people back?
Zika Crisis Stresses Need for Pharma Industry
When pharmaceutical companies are needed, we’re Jonas Salks; when we ask to be paid, we’re Martin Shkrelis.
Right-to-Try Laws Take Sensible Approach to Reforming FDA Rules
The regulator’s reliance on double-blind, placebo-controlled trials with exhaustive inclusion and exclusion criteria is incompatible with today’s precision medicine.
Your PharmaScope 2016
If we don’t clean up our act and do something about predatory pricing scandals, we’ll wind up with Washington bureaucrats telling us what we can charge for our products.
